NEWS
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has signed an exclusive license agreement with MThera Pharma for NB-01, a potential treatment for painful diabetic neuropathy.
The agreement grants MThera rights to conduct research and clinical trials, including a possible Phase 3 trial in the US and South Korea. This move aligns with NeuroBo's strategy to out-license legacy assets and focus on developing DA-1726 and DA-1241.
MThera, with its expertise in natural medicines and botanical drugs, plans to utilize its SyMthomics platform to identify NB-01's mechanism of action and active ingredients.
This approach aims to predict clinical efficacy and advance NB-01 into further clinical development, building on its positive Phase 2 resultsfor diabetic neuropathy.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2311Followers
105Following
24KVisitors
Follow
Trytosaveabit : Wish they woulda included the financial terms? Grrrr! Hehehe
Jaguar8 OP Trytosaveabit : Exactly.